Početna › Difuzni veliki B-stanični limfom › Utah
Kliničke studije za Difuzni veliki B-stanični limfom u državi Utah
14 studija za Difuzni veliki B-stanični limfom traži sudionike na lokacijama u državi Utah.
Gradovi u državi Utah
Službeni tekst studije (engleski)
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- Intermountain Health LDS Hospital, Salt Lake City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06500273A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Community Cancer Trials of Utah, Ogden
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Intermountain Medical Center ( Site 0182), Murray
- Intermountain Healthcare - St. George ( Site 0203), St. George
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06890884A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Intermountain Healthcare, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
- Huntsman Cancer Institute, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT06227026Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Intermountain Healthcare, Salt Lake City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- Huntsman Cancer Institute, University of Utah, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. srp 2026. · NCT05077527External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
- Huntsman Cancer Institute at University of Utah, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. lip 2026. · NCT07528352A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- Huntsman Cancer Institute, University of Utah, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. ožu 2026. · NCT04830137Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Huntsman Cancer Institute, University of Utah, Salt Lake City
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT04775745Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Huntsman Cancer Institute/University of Utah, Salt Lake City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 20. lis 2025. · NCT05890352Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy
- Huntsman Cancer Institute/University of Utah, Salt Lake City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 26. ruj 2024. · NCT06238648Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.